Eton Pharmaceuticals Acquires New Drug Application
On October 4, Eton Pharmaceuticals, Inc. announced it entered into an agreement to acquire an abbreviated new drug application for Nitisinone Capsules from Oakrum Pharma, LLC. This transaction is part of Oakrum Pharma’s Chapter 11 bankruptcy proceedings. Nitisinone Capsules were approved by the FDA in May 2023 for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. Oakrum Pharma is a biopharmaceutical company focusing on development and commercialization of affordable drug therapies Eton Pharmaceuticals is an innovative pharmaceutical company focused on developing, acquiring and commercializing products to address... Read More »
Alfasigma Acquires Intercept Pharmaceuticals
Alfasigma S.p.A announced on September 25 that it acquired Intercept Pharmaceuticals for more than $793.87 million. According to data captured in the LevinPro HC database, this transaction represents the 81st Pharmaceutical acquisition of the year. Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis and severe alcohol-associated hepatitis. The company announced revenues of $285.71 million for the full year ending on December 31, 2022. One of Intercept’s lead products is Ocaliva®, which is the only FDA-approved... Read More »
Murphy Canyon Acquisition Corp. Merges with Conduit Pharmaceuticals
Murphy Canyon Acquisition Corp. (MURF) announced on September 22 the completion of its previously announced merger with Conduit Pharmaceuticals Inc. for a pro forma enterprise value of approximately $720 million. According to data captured in the LevinPro HC database, this transaction represents the 79th Pharmaceuticals transaction of the year. Conduit is a disease agnostic life science company providing an efficient model for compound development. Conduit acquires assets that are Phase II-ready and then seeks an exit through third-party license deals following successful clinical trials. Led by a team of pharmaceutical executives, it was established to fund the development of... Read More »
Pharmanovia Acquires CNS Portfolio From Sanofi
Pharmanovia announced on September 18 the expansion of its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from global healthcare company, Sanofi. According to data captured in the LevinPro HC database, this transaction is the 75th Pharmaceutical acquisition of 2023. Sanofi is selling a portfolio of CNS brands, including Frisium®, Sentil®, Urbanyl®, Urbanil®, Urbanol®, Urbadan®, Noiafren®, Castilium®, Gardenal®, Tercian® and Stemetil®. The brands span four therapy areas of ongoing unmet need associated with CNS disorders – psycholeptic, anxiolytic, anti-epileptic and anti-psychotic. Pharmanovia (formerly known as Atnahs Pharma UK Limited) is a... Read More »
Waud Capital Partners Launches PharmAlliance Holdings
Waud Capital Partners, a growth-oriented middle market private equity firm based in Chicago, announced on September 14 that it launched PharmAlliance Holdings, LLC. This was done in partnership with Mark Bouck, who will serve as Chief Executive Officer of the platform. PharmAlliance Holdings is a diversified pharmaceutical and life sciences services provider focused on discovery, development and commercialization solutions. Its services span across the drug life cycle for pharmaceutical, biotechnology, life sciences and medical device companies. In conjunction with its launch, PharmAlliance invested in BioBridges, a drug development consulting business serving... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
